ClassID:

20412

A61K31/4985 - page 4 - CPC Classification

Classification description:

Medicinal preparations containing organic active ingredients; Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two nitrogen atoms as the only ring heteroatoms, e.g. piperazine Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems

Recent Application in this class:
#901
20220298165
2022-09-22

Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-α]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof

#902
20220296616
2022-09-22

SHP1 AND SHP2 INHIBITORS AND THEIR METHODS OF USE

#903
20220296602
2022-09-22

Liquid oral formulations for tadalafil

#904
20220296591
2022-09-22

ORGANIC COMPOUNDS

#905
20220296590
2022-09-22

STEREOISOMERS OF THE COMPOUND 3-(BENZO[D][1,3]DIOXOL-5-YL)-7-(1-HYDROXYPROPAN-2-YL)-1-(1H-INDOL-3-YL)-6,7-DIHYDRO-3H-OXAZOL[3,4-A]PYRAZINE-5,8-DIONE AND USE THEREOF AS AN ANTITUMOR AGENT AND PHOSPHODIESTERASE ENZYME INHIBITOR

#906
20220296539
2022-09-22

Metformin glycinate, pharmaceutical compositions comprising the same, and methods of using the same

#907
20220289753
2022-09-15

SHP2 INHIBITORS

#908
20220288197
2022-09-15

METHODS OF TREATING A SUBJECT WITH A CDC42-SPECIFIC INHIBITOR

#909
20220288025
2022-09-15

COMPOSITIONS AND METHODS FOR TREATING HEMORRHAGIC STROKE

#910
20220288020
2022-09-15

METHOD OF TREATING NEOPLASTIC DISEASES WITH A CDC42-SPECIFIC INHIBITOR

#911
20220281882
2022-09-08

PROCESSES FOR THE PREPARATION OF (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1,2-a]PYRROLO[2,3-e]-PYRAZIN-8-YL)-N-(2,2,2-TRIFLUOROETHYL)PYRROLIDINE-1-CARBOXAMIDE AND SOLID STATE FORMS THEREOF

#912
20220281825
2022-09-08

HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF ARENAVIRUS INFECTION

#913
20220280508
2022-09-08

PHARMACEUTICAL COMPOSITION FOR TREATING AFRICAN SWINE FEVER AND USE THEREOF

#914
20220280507
2022-09-08

USES OF 5-METHYLTETRAHYDROFOLATE AND ITS COMPOSITION

#915
20220273651
2022-09-01

Methods of treating crohn's disease and ulcerative colitis

#916
20220273650
2022-09-01

TREATMENT OF CANCER WITH TOR KINASE INHIBITORS

#917
20220273557
2022-09-01

COMPOSITIONS AND METHODS FOR TREATMENT OF PRESBYOPIA

#918
20220267342
2022-08-25

Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof

#919
20220267340
2022-08-25

DOSAGE FORM COMPOSITIONS COMPRISING AN INHIBITOR OF BRUTON'S TYROSINE KINASE

#920
20220265652
2022-08-25

COMBINATION THERAPY OF GPR119 AGONISTS AND DPP-4 INHIBITORS

#921
20220265649
2022-08-25

BILE ACID RECYCLING INHIBITORS FOR TREATMENT OF PEDIATRIC CHOLESTATIC LIVER DISEASES

#922
20220265648
2022-08-25

Bromocriptine formulations

#923
20220257615
2022-08-18

COMBINATION FOR THE TREATMENT OF INFECTIONS CAUSED BY MYCOPLASMA GENITALIUM

#924
20220257600
2022-08-18

Treatment of a disease of the gastrointestinal tract with a JAK or other kinase inhibitor

#925
20220251212
2022-08-11

ANTI-PD-L1 COMBINATIONS FOR TREATING TUMORS

#926
20220251162
2022-08-11

PAC1 receptor agonists (MAXCAPs) and uses thereof

#927
20220251113
2022-08-11

Nitrogen-containing condensed ring compounds having dopamine D3 antagonistic effect

#928
20220251101
2022-08-11

Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof

#929
20220249489
2022-08-11

METHOD FOR TREATING CANCER USING A COMBINATION OF CHK1 AND ATR INHIBITORS

#930
20220249475
2022-08-11

COMPOUNDS AND METHOD FOR TREATING CYTOKINE RELEASE SYNDROME

#931
20220249473
2022-08-11

A NOVEL THERAPY FOR ERYTHROPOIETIC PROTOPORPHYRIA (EPP) AND X-LINKED PROTOPORPHYRIA (XLP)

#932
20220249472
2022-08-11

Administration of antipsychotics

#933
20220249465
2022-08-11

UNIT DOSAGE FORM FOR TRANSMUCOSAL DRUG DELIVERY OF AN ACTIVE PHARMACEUTICAL INGREDIENT

#934
20220241617
2022-08-04

Pulmonary hypertension treatment

#935
20220241276
2022-08-04

COMPOSITIONS AND METHODS FOR TREATING CANCER

#936
20220241261
2022-08-04

COMBINATIONS OF INHIBITORS OF IRAK4 WITH INHIBITORS OF BTK

#937
20220235018
2022-07-28

METHODS USING HDAC11 INHIBITORS

#938
20220233567
2022-07-28

Adenosine derivative and pharmaceutical composition comprising the same

#939
20220233549
2022-07-28

METHOD FOR ALPHAVIRUS INHIBITION

#940
20220233528
2022-07-28

Compositions and use of varenicline for treating dry eye

#941
20220233527
2022-07-28

Methods of treating Crohn's disease and ulcerative colitis

#942
20220233526
2022-07-28

COMBINATION OF HEPATITIS B VIRUS (HBV) VACCINES AND DIHYDROPYRIMIDINE DERIVATIVES AS CAPSID ASSEMBLY MODULATORS

#943
20220233525
2022-07-28

Substituted pyrido[1,2-a]pyrrolo[1,2-d]pyrazines for treating viral infections

#944
20220233513
2022-07-28

COMPOUND USED AS RET KINASE INHIBITOR AND APPLICATION THEREOF

#945
20220227709
2022-07-21

COMPOSITIONS AND METHODS FOR TREATING SCHISTOSOMA INFECTIONS

#946
20220226332
2022-07-21

Phosphodiesterase Inhibitor Treatment

#947
20220226331
2022-07-21

INTEGRATION OF MOLECULAR MECHANISMS IN THE STRIATUM AS A COMBINATION DRUG STRATEGY FOR THE TREATMENT OF PSYCHIATRIC AND NEUROLOGICAL DISORDERS IN WHICH ANHEDONIA OR MOTIVATION-RELATED DYSFUNCTION EXISTS

#948
20220226317
2022-07-21

SYNERGISTIC COMBINATIONS AND METHODS OF USE

#949
20220226316
2022-07-21

SYNERGISTIC COMBINATIONS AND METHODS OF USE

#950
20220226315
2022-07-21

SYNERGISTIC COMBINATIONS AND METHODS OF USE

#951
20220226308
2022-07-21

Parenteral unit dosage form of dihydroergotamine

#952
20220226283
2022-07-21

COMBINATION PRODUCT CONTAINING LIMONOID COMPOUND AND DPP-4 INHIBITOR

#953
20220213121
2022-07-07

SUBSTITUTED 1,2,3,3a,4,5,7,9,13,13a-DECAHYDROPYRIDO[1',2':4,5]PYRAZINO[1,2-a]PYRROLO[1,2-c]PYRIMIDINES HAVING HIV INTEGRASE INHIBITORY ACTIVITY

#954
20220213106
2022-07-07

Inhibitors of Bruton's Tyrosine Kinase

#955
20220211802
2022-07-07

Endoparasitic depsipeptides

#956
20220211706
2022-07-07

Methods and Compositions for Treating Cancer

#957
20220211704
2022-07-07

INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION

#958
20220204482
2022-06-30

Compounds and methods for treating cancer

#959
20220202936
2022-06-30

Agent for use in the treatment of glioma

#960
20220202813
2022-06-30

Amorphous solid dispersions

#961
20220202791
2022-06-30

COMPOSITIONS AND METHODS FOR THE TREATMENT OF ADDICTION AND OTHER NEUROPSYCHIATRIC DISORDERS

#962
20220195056
2022-06-23

METHOD OF TREATING KELOIDS

#963
20220193073
2022-06-23

Method of treating fibrosis

#964
20220193062
2022-06-23

COMBINATION OF ENZASTAURIN AND INHIBITORS OF BTK AND USES THEREOF

#965
20220184088
2022-06-16

Uses of DPP IV inhibitors

#966
20220184072
2022-06-16

METHODS OF TREATING NEUROPATHIC PAIN

#967
20220184071
2022-06-16

GEPOTIDACIN FOR USE IN THE TREATMENT OF BACTERIAL URINARY TRACT INFECTIONS

#968
20220184070
2022-06-16

LOW-DOSE TRIPLE COMBINATION FORMULATION

#969
20220184069
2022-06-16

Methods of treating splenomegaly

#970
20220177476
2022-06-09

Crystal Forms of (S)-4-(8-amino-3-(1-(but-2-ynoyl)-pyrrolidin-2-yl)imidazo[1,5-a]pyrazin-1-yl)-n-(pyridin-2-yl)benzamide

#971
20220177470
2022-06-09

Sulfoximine glycosidase inhibitors

#972
20220175818
2022-06-09

Inhibition of Monoamine Oxidase Subtype A (MAOA) Mitigates Cardiovascular Calcification

#973
20220175770
2022-06-09

TREATMENT OF HEPATOCELLULAR CARCINOMA CHARACTERIZED BY HEPATITIS B VIRUS INFECTION

#974
20220168308
2022-06-02

METHODS FOR TREATING ALZHEIMER DISEASE AND FOR REDUCING AMYLOID BETA FORMATION

#975
20220168286
2022-06-02

TREATMENT OF RAYNAUD'S DISEASE

#976
20220168268
2022-06-02

SMALL-MOLECULE INHIBITOR OF PD-1/PD-L1, PHARMACEUTICAL COMPOSITION THEREOF WITH PD-L1 ANTIBODY, AND APPLICATION OF SAME

#977
20220160705
2022-05-26

METHODS FOR CONTROLLING PROSTAGLANDIN-MEDIATED BIOLOGICAL PROCESSES

#978
20220152069
2022-05-19

Compounds and pharmaceutical uses thereof

#979
20220151976
2022-05-19

TARGETING LASP1, EIF4A1, EIF4B AND CXC4 WITH MODULATORS AND COMBINATIONS THEREOF FOR CANCER THERAPY

#980
20220143186
2022-05-12

SOLIDIFICATION OR CRYSTALLISATION METHOD

#981
20220143034
2022-05-12

PDE5 inhibitor powder formulations and methods relating thereto

#982
20220142932
2022-05-12

Methods of treatment using pharmaceutical capsule compositions comprising lumateperone mono-tosylate

#983
20220142920
2022-05-12

Praziquantel Formulations

#984
20220135967
2022-05-05

TUNABLE ENDOGENOUS PROTEIN DEGRADATION

#985
20220133718
2022-05-05

PHARMACEUTICAL FORMULATIONS, PROCESSES FOR PREPARATION, AND METHODS OF USE

#986
20220133717
2022-05-05

RABEXIMOD IN THE TREATMENT OF RHEUMATOID ARTHRITIS

#987
20220127253
2022-04-28

COMPOUNDS FOR PREVENTING, INHIBITING, OR TREATING CANCER, AIDS AND/OR PREMATURE AGING

#988
20220125933
2022-04-28

LIPID PRODRUGS OF JAK INHIBITORS AND USES THEREOF

#989
20220125787
2022-04-28

Compounds and compositions for treating conditions associated with APJ receptor activity

#990
20220125786
2022-04-28

SUBSTITUTED BENZALDEHYDE COMPOUNDS AND METHODS FOR THEIR USE IN INCREASING TISSUE OXYGENATION

#991
20220125785
2022-04-28

2-(3′-(hydroxymethyl)-1-methyl-5-((5-(2-methyl-4-(oxetan-3-yl)piperazin-1-yl)pyridin-2-yl)amino)-6-oxo-1,6-dihydro-[3,4′-bipyridin]-2′-yl)-7,7-dimethyl-7,8-dihydro-2H-cyclopenta[4,5]pyrrolo[1,2-a]pyrazin-1(6H)-one as a BTK inhibitor

#992
20220125780
2022-04-28

SUBSTITUTED TETRAHYDROQUINOLINONE COMPOUNDS AS ROR GAMMA MODULATORS

#993
20220125746
2022-04-28

METHOD OF PREVENTING OR TREATING TREATMENT-INDUCED GASTROINTESTINAL INJURY

#994
20220118003
2022-04-21

PHARMACEUTICAL COMPOSITION

#995
20220117960
2022-04-21

Dipeptidylpeptidase 4 inhibition enhances lymphocyte trafficking, improving both naturally occurring tumor immunity and immunotherapy

#996
20220117959
2022-04-21

LIQUID PHARMACEUTICAL COMPOSITIONS

#997
20220117916
2022-04-21

Combination Products to Mitigate the Risk of Non-Benzodiazepine Benzodiazepine Agonist Adverse Reaction and Overdose

#998
20220110933
2022-04-14

METHODS OF TREATING DISEASE WITH MAGL INHIBITORS

#999
20220105096
2022-04-07

INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION

#1000
20220105091
2022-04-07

FUSED TRICYCLIC PYRAZOLO-DIHYDROPYRAZINYL-PYRIDONE COMPOUNDS AS ANTIVIRALS

#1001
20220096535
2022-03-31

COMBINATION DRUG THERAPIES OF PDE-5 INHIBITORS AND INHALED NITRIC OXIDE

#1002
20220096476
2022-03-31

Pharmaceutical composition for the treatment of pulmonary arterial hypertension

#1003
20220096469
2022-03-31

PHARMACEUTICAL COMPOSITIONS

#1004
20220089749
2022-03-24

Anti-EGFR combinations for treating tumors

#1005
20220088201
2022-03-24

LINEAR POLYSACCHARIDE BASED FILM PRODUCTS

#1006
20220088022
2022-03-24

Therapeutic regimen

#1007
20220088015
2022-03-24

METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF AGE-RELATED CARDIOMETABOLIC DISEASES

#1008
20220088014
2022-03-24

METHODS OF TREATING ADDICTION

#1009
20220088013
2022-03-24

Therapeutic combinations of a BTK inhibitor, a PI3K inhibitor, a JAK-2 inhibitor, and/or a BCL-2 inhibitor

#1010
20220087970
2022-03-24

PREVENTION OF ANESTHETIC-INDUCED NEUROCOGNITIVE DYSFUNCTION

#1011
20220087958
2022-03-24

Antidiabetic pharmaceutical compositions and preparation method thereof

#1012
20220081427
2022-03-17

INHIBITORS OF JUN N-TERMINAL KINASE

#1013
20220079895
2022-03-17

COMPOSITION FOR PREVENTING OR TREATING LIVER DISEASES

#1014
20220073530
2022-03-10

Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof

#1015
20220071991
2022-03-10

EXTENDED RELEASE COMPOSITIONS OF OPIOID ANTAGONISTS AND PHOSPHODIESTERASE 5 INHIBITORS

#1016
20220071928
2022-03-10

Polyamine transport inhibitors as antivirals

#1017
20220064171
2022-03-03

Diketopiperazine derivatives as calcium ATPase inhibitor for enhancing anticancer activity

#1018
20220062379
2022-03-03

METHODS AND COMPOSITIONS FOR MODULATING IMMUNE DYSREGULATION

#1019
20220062307
2022-03-03

METHODS AND MATERIALS FOR TREATING CALCIFIC AORTIC VALVE STENOSIS

#1020
20220062293
2022-03-03

MODULATORS OF TOLL-LIKE RECEPTORS FOR THE TREATMENT OF HIV

#1021
20220062194
2022-03-03

Treatment of Addiction and Impulse-Control Disorders Using PDE7 Inhibitors

#1022
20220062166
2022-03-03

Self-Gelling Solutions for Administration of Therapeutics to the Inner Ear

#1023
20220056024
2022-02-24

Pyridopyrazine and pyridotriazine inhibitors of influenza virus replication

#1024
20220054496
2022-02-24

MODULATION OF TRF1 FOR BRAIN CANCER TREATMENT

#1025
20220054492
2022-02-24

Combination therapies

#1026
20220054485
2022-02-24

METHODS OF TREATING RIGHT VENTRICULAR FUNCTION IN PULMONARY HYPERTENSION

#1027
20220054418
2022-02-24

Methods for the preparation of biologically active compounds in nanoparticulate form

#1028
20220048910
2022-02-17

ORGANIC COMPOUNDS

#1029
20220047589
2022-02-17

PDE9 INHIBITORS FOR TREATING THALASSEMIA

#1030
20220047588
2022-02-17

METHODS OF TREATING RHEUMATOID ARTHRITIS, CHRONIC SPONTANEOUS URTICARIA, AND SYSTEMIC LUPUS ERYTHEMATOSIS USING AN INHIBITOR OF BRUTON'S TYROSINE KINASE

#1031
20220047587
2022-02-17

SYNERGISTIC COMPOSITIONS COMPRISING R-2-(SUBSTITUTED-SULFONYL)-HEXAHYDRO-PYRROLO[1,2-A]PYRAZIN-6(2H)-ONES AND S-2-(SUBSTITUTED-SULFONYL)-HEXAHYDRO-PYRROLO[1,2-A]PYRAZIN-6(2H)-ONES IN A NON-RACEMIC RATIO

#1032
20220047569
2022-02-17

METHOD AND COMPOUND FOR USE, IN TREATING AND/OR PREVENTING NETOSIS

#1033
20220047541
2022-02-17

PHARMACEUTICAL COMPOSITIONS AND METHODS FOR TREATING PARKINSON'S DISEASE

#1034
20220047514
2022-02-17

SOLID ORAL PHARMACEUTICAL COMPOSITIONS FOR CHRONOTROPIC ADMINISTRATION OF DIPEPTIDYL PEPTIDASE IV INHIBITORS

#1035
20220047506
2022-02-17

Praziquantel Formulations

#1036
20220040304
2022-02-10

A COMPOSITION FOR CANCER CELL DEATH AND ITS USE

#1037
20220040184
2022-02-10

SUBSTITUTED AMINO TRIAZOLOPYRIMIDINE AND AMINO TRIAZOLOPYRAZINE ADENOSINE RECEPTOR ANTAGONISTS, PHARMACEUTICAL COMPOSITIONS AND THEIR USE

#1038
20220031703
2022-02-03

Solid pharmaceutical compositions comprising biopterin derivatives and uses of such compositions

#1039
20220023296
2022-01-27

Bile acid recycling inhibitors for treatment of pediatric cholestatic liver diseases

#1040
20220017559
2022-01-20

CYCLIC PEROXIDES AS PRODRUGS FOR SELECTIVE DELIVERY OF AGENTS

#1041
20220017537
2022-01-20

Compositions and methods for regulating glucose homeostasis and insulin action

#1042
20220016126
2022-01-20

PDE5 inhibitor powder formulations and methods relating thereto

#1043
20220016119
2022-01-20

METHODS AND TREATMENTS FOR ERECTILE DYSFUNCTION

#1044
20220016112
2022-01-20

Dihydroquinoxaline and dihydropyridopyrazine derivatives as RSV inhibitors

#1045
20220009937
2022-01-13

SGC stimulators

#1046
20220008554
2022-01-13

NOVEL NANOPARTICLES OF ANTIRETROVIRAL DRUGS, THEIR PREPARATION AND THEIR USE FOR THE TREATMENT OF VIRAL INFECTIONS

#1047
20220008423
2022-01-13

Organic compounds

#1048
20220008419
2022-01-13

PHARMACEUTICAL COMPOSITION FOR TREATING DIFFUSE-TYPE GASTRIC CANCER

#1049
20220008415
2022-01-13

Combination Therapy for Male Sexual Dysfunction

#1050
20220008405
2022-01-13

Inhibitors of SARM1 in combination with neuro-protective agents

#1051
20220000866
2022-01-06

THERAPEUTIC AGENT COMPOSITION AND METHOD OF USE, FOR TREATMENT OF MILD CONGNITIVE IMPAIRMENT, DEPRESSION, AND PSYCHOLOGICAL DISORDERS

#1052
20210401850
2021-12-30

ANTIVIRAL THERAPY

#1053
20210401835
2021-12-30

Methods of treating chronic lymphocytic leukemia and small lymphocytic leukemia using a BTK inhibitor

#1054
20210401824
2021-12-30

Parenteral Formulations of Dopamine Agonists

#1055
20210393635
2021-12-23

Liquid oral formulations for sildenafil

#1056
20210393623
2021-12-23

Novel Heterocyclic Derivatives Useful as SHP2 Inhibitors

#1057
20210386744
2021-12-16

SILDENAFIL FOR USE IN THE TREATMENT OF OSTEOARTHRITIS

#1058
20210386735
2021-12-16

Methods of Treating Acute HCV

#1059
20210386709
2021-12-16

COMPOSITIONS AND METHODS FOR SUPPRESSING MSUT2

#1060
20210379171
2021-12-09

Ovarian cancer vaccines

#1061
20210379059
2021-12-09

COMBINATION OF SUBSTANCES FOR REGENERATIVE THERAPY IN PATIENTS WITH TYPE 1 DIABETES MELLITUS

#1062
20210379033
2021-12-09

METHODS OF TREATING CANCER WITH ARYL HYDROCARBON RECEPTOR ANTAGONISTS

#1063
20210379020
2021-12-09

COMPOUNDS FOR THE TREATMENT OF MALARIA

#1064
20210378991
2021-12-09

Engaging the cervical spinal cord circuitry to re-enable volitional control of hand function in tetraplegic subjects

#1065
20210371421
2021-12-02

Compounds and methods

#1066
20210369717
2021-12-02

Liquid oral formulations for tadalafil

#1067
20210369707
2021-12-02

Uses

#1068
20210369652
2021-12-02

Nonhormonal Unisex Contraceptives

#1069
20210363149
2021-11-25

PROCESSES FOR THE PREPARATION OF (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1,2-a]PYRROLO[2,3-e]-PYRAZIN-8-YL)-N-(2,2,2-TRIFLUOROETHYL)PYRROLIDINE-1-CARBOXAMIDE AND SOLID STATE FORMS THEREOF

#1070
20210361659
2021-11-25

Treatment of congenital adrenal hyperplasia

#1071
20210361648
2021-11-25

Transmucosal methods for treating psychiatric and neurological conditions

#1072
20210361647
2021-11-25

METHODS OF TREATING CROHN'S DISEASE AND ULCERATIVE COLITIS

#1073
20210361631
2021-11-25

N-methyl-D-aspartic acid receptor modulators

#1074
20210361607
2021-11-25

COMBINATION METHODS AND COMPOSITIONS INCLUDING SLEEP THERAPEUTICS FOR TREATING MOOD

#1075
20210355127
2021-11-18

Pyrazole derivatives useful as 5-lipoxygenase activating protein (FLAP) inhibitors

#1076
20210347813
2021-11-11

COMPOUNDS WITH HIV MATURATION INHIBITORY ACTIVITY

#1077
20210346385
2021-11-11

TASTE-MASKED DOSAGE FORMS

#1078
20210346382
2021-11-11

BTK Inhibitors to Treat Solid Tumors Through Modulation of the Tumor Microenvironment

#1079
20210346377
2021-11-11

Fused tricyclic pyrazolo-dihydropyrazinyl-pyridone compounds as antivirals

#1080
20210346353
2021-11-11

CD73 inhibitors

#1081
20210338779
2021-11-04

THERAPEUTIC USE OF GLUCAGON AND COMBINATION INCLUDING THE SAME

#1082
20210338678
2021-11-04

BIOACTIVE VITAMIN COMBINATIONS

#1083
20210338666
2021-11-04

BRIMONIDINE COMBINATIONS AND USES THEREOF

#1084
20210332065
2021-10-28

BCL-2 inhibitors

#1085
20210322456
2021-10-21

BENZIMIDAZOLES THAT ENHANCE THE ACTIVITY OF OLIGONUCLEOTIDES

#1086
20210322433
2021-10-21

NOVEL METHODS

#1087
20210322420
2021-10-21

Fused heterotricyclic organic compounds, pharmaceutical compositions, and medical uses thereof

#1088
20210322408
2021-10-21

Methods of Treating Cancers, Immune and Autoimmune Diseases, and Inflammatory Diseases Based on BTK Occupancy and BTK Resynthesis Rate

#1089
20210322405
2021-10-21

COMPOSITIONS AND METHODS FOR TREATING CANCER

#1090
20210315904
2021-10-14

BCL-2 inhibitors

#1091
20210315891
2021-10-14

Compositions and methods

#1092
20210315890
2021-10-14

Dipeptidyl peptidase-4 inhibitors for topical eye treatment of retinal neurodegenerative diseases

#1093
20210311061
2021-10-07

USE OF TROP-2 AS PREDICTIVE MARKER OF RESPONSE TO ANTI-TUMOR THERAPY BASED ON INHIBITORS OF CD9, AKT AND MOLECULES OF THE TETRASPANIN SIGNALLING NETWORK

#1094
20210309667
2021-10-07

Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof

#1095
20210308131
2021-10-07

Treatment Regimen

#1096
20210301286
2021-09-30

TARGETED PROTEIN DEGRADATION TO ATTENUATE ADOPTIVE T-CELL THERAPY ASSOCIATED ADVERSE INFLAMMATORY RESPONSES

#1097
20210299128
2021-09-30

Compounds for treating or inhibiting recurrence of acute myeloid leukemia

#1098
20210299124
2021-09-30

Pharmaceutical capsule compositions comprising lumateperone mono-tosylate

#1099
20210299123
2021-09-30

Survivin-targeting anti-tumor agents and uses thereof

#1100
20210290826
2021-09-23

Biomaterial and method for promoting tissue regeneration by using the biomaterial

#1101
20210290619
2021-09-23

SUBSTITUTED BENZALDEHYDE COMPOUNDS AND METHODS FOR THEIR USE IN INCREASING TISSUE OXYGENATION

#1102
20210283138
2021-09-16

Substituted indole Mcl-1 inhibitors

#1103
20210283094
2021-09-16

COMBINATION THERAPY USING LOW-DOSE DOXEPIN FOR THE IMPROVEMENT OF SLEEP

#1104
20210283069
2021-09-16

Use of cannabinoids in treating anti-depressant-induced female sexual dysfunction

#1105
20210277007
2021-09-09

Hetero-halo inhibitors of histone deacetylase

#1106
20210275531
2021-09-09

PHOSPHODIESTERASE-5 INHIBITOR COMBINATIONS, METHODS OF MAKING, AND METHODS OF USE THEREOF

#1107
20210275347
2021-09-09

INTRAVAGINAL RING DEVICES

#1108
20210267951
2021-09-02

COMBINATION THERAPY FOR PULMONARY HYPERTENSION

#1109
20210260056
2021-08-26

LOW-DOSE TRIPLE COMBINATION FORMULATION

#1110
20210260040
2021-08-26

METHODS OF USING EHMT2 INHIBITORS IN TREATING OR PREVENTING BLOOD DISORDERS

#1111
20210253598
2021-08-19

ARYL ANNULATED MACROCYCLIC INDOLE DERIVATIVES

#1112
20210253291
2021-08-19

ORODISPERSIBLE FILMS HAVING QUICK DISSOLUTION TIMES FOR THERAPEUTIC AND FOOD USE

#1113
20210251994
2021-08-19

INCREASING IMMUNE ACTIVITY THROUGH MODULATION OF POSTCELLULAR SIGNALING FACTORS

#1114
20210251945
2021-08-19

Compounds and pharmaceutical uses thereof

#1115
20210238167
2021-08-05

SMALL MOLECULE IRE1-ALPHA INHIBITORS

#1116
20210236501
2021-08-05

COMBINATION THERAPY FOR PI3K-ASSOCIATED DISEASE OR DISORDER

#1117
20210236486
2021-08-05

Treating untreated or treatment-resistant diabetes with glucokinase activator

#1118
20210236485
2021-08-05

REPEATED ADMINISTRATION OF DIHYDROERGOTAMINE FOR TREATMENT OF FREQUENT MIGRAINE HEADACHES

#1119
20210236484
2021-08-05

Method of reducing pulmonary exacerbations in respiratory disease patients

#1120
20210230294
2021-07-29

CD73 inhibitor and A2A/A2B adenosine receptor inhibitor combination therapy

#1121
20210230276
2021-07-29

TREATMENT OF CANCER WITH COMBINATIONS OF IMMUNOREGULATORY AGENTS

#1122
20210230166
2021-07-29

4-IMIDAZOPYRIDAZIN-1-YL-BENZAMIDES AS BTK INHIBITORS

#1123
20210228576
2021-07-29

Bromocriptine formulations

#1124
20210228575
2021-07-29

TREATING SPONDYLOARTHRITIC AND PSORIATIC CONDITIONS WITH UPADACITINIB

#1125
20210228565
2021-07-29

Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases

#1126
20210228563
2021-07-29

Methods of treating RBP4 related diseases with triazolopyridines

#1127
20210220365
2021-07-22

Treatment of autism spectrum disorders, obsessive-compulsive disorder and anxiety disorders

#1128
20210220334
2021-07-22

Pharmaceutical combination, composition and compound preparation containing glucokinase activator and K-ATP channel blocker, preparation method therefor and use thereof

#1129
20210220280
2021-07-22

Methods

#1130
20210214343
2021-07-15

Pharmaceutical combination, composition, and combination preparation comprising glucokinase activator and SGLT-2 inhibitor and preparation methods and uses thereof

#1131
20210214323
2021-07-15

NOVEL COMPOUNDS AND COMPOSITIONS FOR INHIBITION OF FASN

#1132
20210213021
2021-07-15

TOPICAL COMPOSITIONS FOR STIMULATING HAIR GROWTH

#1133
20210213012
2021-07-15

Combinations of estrogen receptor degraders and cyclin-dependent kinase inhibitors for treating cancer

#1134
20210212991
2021-07-15

Pharmaceutical combination containing glucose kinase activator and PPAR receptor activator, composition, compound preparation method for same, and uses thereof

#1135
20210207199
2021-07-08

Genetic Predictors of a Response to Treatment with CRHR1 Antagonists

#1136
20210205322
2021-07-08

RICTOR-TARGETED THERAPY IN THE MANAGEMENT OF BRAIN METASTASES

#1137
20210205311
2021-07-08

Combination Therapy Comprising A2A/A2B and PD-1/PD-L1 Inhibitors

#1138
20210196823
2021-07-01

Methods of Treating Metabolic Disease

#1139
20210196715
2021-07-01

Pharmaceutical composition for the treatment of pulmonary arterial hypertension

#1140
20210196713
2021-07-01

Small molecule inhibitors of cancer stem cells and mesenchymal cancer types

#1141
20210196712
2021-07-01

METHODS OF TREATING COCHLEAR SYNAPTOPATHY

#1142
20210196683
2021-07-01

Pharmaceutical combination and composition, and combination preparation containing glucokinase activator and biguanide hypoglycemic drug as well as preparation method and use thereof

#1143
20210196682
2021-07-01

Pharmaceutical combination, composition and compound preparation comprising glucokinase activator and DPP-IV inhibitor, and preparation method and use thereof

#1144
20210188859
2021-06-24

Crystal form of ACP-196 and method of treatment thereof

#1145
20210188850
2021-06-24

Organic compounds

#1146
20210186963
2021-06-24

Small molecule inhibitors of the nuclear translocation of androgen receptor for the treatment of castration-resistant prostate cancer

#1147
20210186962
2021-06-24

METHODS OF SCHIZOPHRENIA TREATMENT

#1148
20210186961
2021-06-24

CARBOXAMIDE DERIVATIVES USEFUL AS RSK INHIBITORS

#1149
20210186960
2021-06-24

MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE

#1150
20210186959
2021-06-24

SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS

#1151
20210186958
2021-06-24

Glycosidase inhibitors

#1152
20210186935
2021-06-24

Rapamycin analogs and uses thereof

#1153
20210179633
2021-06-17

KRas G12C inhibitors

#1154
20210179606
2021-06-17

Compositions comprising macrocycle derivatives incorporating bridged macrocycles and methods of producing and using same

#1155
20210177855
2021-06-17

Bicyclic bromodomain inhibitors

#1156
20210177849
2021-06-17

Therapeutic Compositions

#1157
20210177839
2021-06-17

Bromocriptine formulations

#1158
20210177827
2021-06-17

PAPD5 inhibitors and methods of use thereof

#1159
20210177758
2021-06-17

Platform drug delivery system utilizing crystal engineering and theanine dissolution

#1160
20210169984
2021-06-10

SENSITIZING CANCER TO DEATH RECEPTOR AGONISTS WITH KINASE INHIBITORS

#1161
20210169878
2021-06-10

COMBINATION OF ANTI-CD20 ANTIBODY, P13 KINASE-DELTA SELECTIVE INHIBITOR, AND BTK INHIBITOR TO TREAT B-CELL PROLIFERATIVE DISORDERS

#1162
20210163417
2021-06-03

Isoquinolines as inhibitors of HPK1

#1163
20210161937
2021-06-03

ACTIVATION OF MITOCHONDRIAL UNCOUPLING AS A THERAPEUTIC INTERVENTION

#1164
20210161893
2021-06-03

Use of sGC stimulators for the treatment of nonalcoholic steatohepatitis (NASH)

#1165
20210154192
2021-05-27

Certain triazolopyridines and triazolopyrazines, compositions thereof and methods of use therefor

#1166
20210154179
2021-05-27

Substituted pyridines and methods of use

#1167
20210154178
2021-05-27

ALK5 inhibitors

#1168
20210145840
2021-05-20

T-cell lymphoma treatments

#1169
20210145829
2021-05-20

Organic compounds

#1170
20210139479
2021-05-13

COMT Inhibiting Methods and Compositions

#1171
20210139472
2021-05-13

Ferroportin inhibitors

#1172
20210138028
2021-05-13

Treating or preventing adverse liver conditions

#1173
20210137927
2021-05-13

SOLID PHARMACEUTICAL COMPOSITIONS COMPRISING BIOPTERIN DERIVATIVES AND USES OF SUCH COMPOSITIONS

#1174
20210137926
2021-05-13

Treatment of congenital adrenal hyperplasia

#1175
20210137920
2021-05-13

PHARMACEUTICAL COMPOSITIONS OF SITAGLIPTIN

#1176
20210137919
2021-05-13

PHARMACEUTICAL FORMULATIONS, METHOD FOR PRODUCING A PHARMACEUTICAL FORMULATION, AND MEDICAMENT COMPRISING SAME

#1177
20210130344
2021-05-06

Composition and method for treating metabolic disorders

#1178
20210128680
2021-05-06

METHOD FOR TREATING CARDIOPULMONARY DISORDER

#1179
20210128580
2021-05-06

Treatment for Wolfram syndrome and other endoplasmic reticulum stress disorders

#1180
20210128553
2021-05-06

COMBINATION COMPOSITIONS FOR IMMUNOTHERAPY

#1181
20210128535
2021-05-06

Substituted fused heteroaromatic tricyclic compounds as kinase inhibitors and the use thereof

#1182
20210128527
2021-05-06

COMPOSITIONS AND METHODS FOR TREATING HEMORRHAGIC STROKE

#1183
20210121458
2021-04-29

Bruton's tyrosine kinase inhibitors

#1184
20210115067
2021-04-22

Fused heterocyclic compound

#1185
20210115044
2021-04-22

TRICYCLIC HETEROCYCLE COMPOUNDS USEFUL AS HIV INTEGRASE INHIBITORS

#1186
20210113568
2021-04-22

PREVENTIVE AND/OR THERAPEUTIC AGENT FOR AUTOIMMUNE DISEASE COMPRISING COMPOUND HAVING Btk INHIBITORY ACTIVITY AS ACTIVE INGREDIENT

#1187
20210113551
2021-04-22

SUBSTITUTED TETRAHYDROQUINOLINONE COMPOUNDS AS ROR GAMMA MODULATORS

#1188
20210113549
2021-04-22

Treatment of idiopathic pulmonary fibrosis

#1189
20210113495
2021-04-22

METHOD OF TREATING EPILEPSY OR EPILEPTIC ENCEPHALOPATHY WITH FENFLURAMINE IN PATIENTS WITHOUT PULMONARY HYPERTENSION

#1190
20210107908
2021-04-15

Pharmaceutical compounds

#1191
20210107903
2021-04-15

Bruton's tyrosine kinase inhibitors

#1192
20210100807
2021-04-08

Treatment of erectile dysfunction and other indications

#1193
20210100801
2021-04-08

Pharmaceutical composition for stimulating stem cell division and suppressing bacterial virulence

#1194
20210100798
2021-04-08

Diacylglycerol acyl transferase 2 inhibitor

#1195
20210100796
2021-04-08

Diacylglycerol acyl transferase 2 inhibitor

#1196
20210094951
2021-04-01

Inhibitors of receptor interacting protein kinase I for the treatment of disease

#1197
20210094946
2021-04-01

Composition and method for treating metabolic disorders

#1198
20210094921
2021-04-01

Inhibitors of receptor interacting protein kinase I for the treatment of disease

#1199
20210093634
2021-04-01

Methods

#1200
20210093633
2021-04-01

TREATMENT FOR DIABETES IN PATIENTS INAPPROPRIATE FOR METFORMIN THERAPY